Protalix BioTherapeutics, Inc. (NYSEAM: PLX)
Health Care · Biotechnology · US
$2.40
+0.84% today · +43.4% 1Y
Protalix BioTherapeutics, Inc. (NYSEAM: PLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $191.76M and employs 226 people.
Over the last twelve months the share price has gained 43.4%, trading between 1.52 and 3.19.
Tweenvest scores Protalix BioTherapeutics, Inc. across four factors: quality 58/100, value 29/100, growth 0/100. Its strongest factor is quality.
PLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $191.76M
- Revenue (TTM)
- $80.62M
- P/E
- 10.07
- EPS
- 0.24
- Dividend yield
- —
- Beta (5Y)
- 0.01
- 52-week high
- $3.19
- 52-week low
- $1.52
- Avg volume (3M)
- —
- Shares outstanding
- 80.57M
- Employees
- 226
- Next earnings
- —
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
- ISIN
- US74365A3095
- Listed since
- May 15, 1998
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $153.70 | -3.23% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.